Therapeutics: An undetermined target

In vitro and mouse studies suggest the generic ROS scavenger edaravone could help treat AD. In human neuroblastoma cells, edaravone decreased β-amyloid (Aβ)-induced cell death and neurite collapse compared with no treatment. In a mouse model of AD, oral edaravone decreased memory deficits and Aβ plaque burden compared with vehicle. Next steps could include testing edaravone in additional animal models of AD.

Mitsubishi Tanabe Pharma Corp. markets Radicut edaravone to treat stroke...